TCR2 Therapeutics Inc expected to post a loss of 65 cents a share - Earnings Preview

TCR2 Therapeutics

08/11/2021 18:00

* TCR2 Therapeutics Inc  TCRR.OQ   TCRR.O  is expected to show
no change in quarterly revenue when it reports  results on
November 10 (estimated). 
​* Refinitiv's mean analyst estimate for TCR2 Therapeutics Inc
is for a loss of 65 cents per share. For the same quarter last
year, the company reported a loss of 56 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for TCR2
Therapeutics Inc is $25​, about 72.1% above​ its last closing
price of $6.98. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 30 2021  -0.61       -0.59      -0.64     Missed  -8.8
 Mar. 31 2021  -0.53       -0.53      -0.58     Missed  -10.4
 Dec. 31 2020  -0.52       -0.56      -0.55     Beat    2​
 Sep. 30 2020  -0.54       -0.53      -0.56     Missed  -5.4
 ​​Jun.        -0.67       -0.65      -0.67     Missed  -2.4
 30 2020                                                
 Mar. 31 2020  -0.61       -0.60      -0.65     Missed  -7.4​
 Dec. 31 2019              -0.67      -0.54     Beat    19
 Sep. 30 2019  -0.55       -0.55      -0.58     Missed  -5.1
 This summary was machine generated November 8 at 18:00 GMT.  All
figures in US dollars unless otherwise stated